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Abstract A significant variation in the metastatic pattern
among breast cancer patients exists. Clinical observations
suggest that these differences are related to time to recur-
rence (TTR), thus suggesting a common systemic growth
signal at the time of surgery. Our goal was to identify a
marker for synchronized growth of micrometastases. To
quantify the metastatic pattern at first relapse, 180 patients
with metastatic breast cancer were studied. Standard
deviation (SD) of lesions size and lesion number was cal-
culated and served as a marker for variation. Patients with
low SD (multiple/similar sized lesions) were assumed to
have synchronized growth, whereas patients with high SD
were assumed to have unsynchronized growth. Patients
were grouped according to TTR; early (\ 3 years-) or late
([ 3 years- after surgery). In patients not receiving sys-
temic adjuvant treatment, median SD was significantly
lower in the early group (2.5 mm) compared with 6.4 mm
in the late group (p = 0.005). In node negative patients,
median SD was significantly lower in the early group
(3.0 mm) when compared with the late group (5.7 mm,
p = 0.02). An additional drop in SD was observed imme-
diately after end of adjuvant endocrine therapy. Our results
identify SD as a marker of synchronized metastatic growth
in breast cancer. A metastatic phenotype characterized by
multiple similar sized metastases, suggesting synchronized
onset of growth of micrometastases was predominantly
found in patients recurring early after surgery and was
counteracted by adjuvant treatment. Systemic growth sig-
nals caused by surgery might be antagonized during the
time window following surgery.
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Introduction
Breast cancer has a long natural history and is infamous for
its propensity for late relapses when compared with most
other cancer types [1]. Even clinically undetectable, tiny
tumors can shed malignant cells into the circulation. Sev-
eral biomarkers like ER, Her2, TNM-classification, and
gene expression signatures [2–5] can readily be applied to
predict early local or early distant disease recurrence within
5 years of diagnosis. On the other hand, no biomarkers
have been proven clinically useful to predict late relapse [6,
7]. In cases with delayed relapse, the nonlinearity of dis-
ease progression gives an indication of the presence of
periods with tumor dormancy [8, 9]. Early micrometastatic
foci, single cells, clusters of cells, or microscopic tumors
can be restricted in growth over periods of time by inability
to recruit blood vessels [10], by immunesurveillance [11],
by cell cycle arrest [12], by tumor microenvironment
(TME) interactions [13] as well as by iatrogenic depletion
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of growth stimulatory hormones in the case of ER? breast
cancer [14]. Interestingly, there are several experimental
tumor models suggesting that dormant cancer can turn into
rapidly progressing disease by growth systemic signals [8,
15, 16]. Moreover, systemic growth signals caused by tis-
sue trauma and wound healing has been shown to initiate
and synchronize growth of dormant micrometastases [17,
18]. Also clinical consequences of tissue trauma and
wound healing have been discussed, as recently reviewed
by Ceelen et al. [19]. Although controversial, in a series of
clinical studies on human breast cancer, Demicheli et al.
[20–22] suggest that the tissue trauma caused by the pri-
mary surgery alone is able to alter the growth kinetics of
dormant micrometastases and reduce time to recurrence.
We hypothesize that activation of systemic growth sig-
nal cascade in breast cancer patients with dormant mi-
crometastases might result in synchronized growth and thus
the detection of multiple similar sized macrometastases at
the time of first recurrence. Consequently, the detection of
multiple similar sized metastases might serve as a marker
of synchronized growth kinetics in these patients. In con-
trast, detection of solitary metastases or oligometastases
with large size variation is more likely to occur when the
metastases grow independently in the absence of a syn-
chronizing signal. In the present study, we aimed to
quantify size and number of metastatic lesions in relation to
time between primary surgery and first relapse. We further
hypothesized that growth of dormant micrometastases can
be preceded by a synchronizing event like increased levels
of wound healing associated growth factors following
surgery or sudden withdrawal of anti-endocrine therapy.
Moreover, we suggested that metastatic synchronization
can be quantified by the standard deviation of size and
number of metastases at time of first recurrence, as a
marker of variation in the metastatic pattern. We focused
on two clinically relevant candidate events that could lead
to systemic synchronization of dormant micrometastases
common to a majority of breast cancer patients; wound
healing after primary surgery and cessation of endocrine
adjuvant therapy.
Methods
The study base for this retrospective analysis consists of 209
consecutive patients treated for metastatic breast cancer
between January 2005 and December 2009 at the Depart-
ment of Oncology, Haukeland University Hospital, Norway.
The hospital covers a population of 500,000, and all new
diagnosed metastatic breast cancer patients in the population
are referred to the regional center. All patients registered
with an ICD-10 code for breast cancer (C 50.X) as well as one
or more codes for metastases (C 77.X–C 79.X) were iden-
tified and all diagnoses were verified and validated in the
patient records. Time to recurrence (TTR) was recorded as
time between primary surgery and time of occurrence of first
recorded metastasis. Patients with synchronous metastases
and primaries, patients with evidence of metastatic disease
within 2 months of surgery, patients that did not have their
primary tumor removed, local recurrences, and patients with
secondary (non-breast) cancers were excluded. Cases with
measurable metastatic disease according to RECIST 1.1,
modified by inclusion of both lytic and blastic bone lesions,
were studied. Blastic bone metastases occur frequently in
breast cancer and were regarded as evaluable for the pur-
poses of this study. Thus, 180 patients were available for
analyses of metastatic pattern.
At the time of first relapse, all patients underwent
thorough staging with radiology, biochemistry, and clinical
examination. Most patients were subjected to multiple
radiology modalities like CT-scan, bone scan, MRI, ultra-
sound, and chest X-ray. All radiology and clinical tumor
measurements were re-examined and the following vari-
ables were recorded; radiology modality, size of each
metastatic lesion according to modified RECIST 1.1,
number of metastases, and affected organs. Patients with
more than 10 metastases were recorded as ‘‘[10’’. For each
case, the standard deviation (SD) of the different sizes of
the metastases was calculated. SD was used as a marker for
variability in the metastatic pattern. Thus, a patient with
multiple similar sized metastases at the time of first
recurrence would present with a ‘‘low SD’’ (Fig. 1a),
whereas a patient with, i.e., one large and two small
metastases would have a ‘‘high SD’’ (Fig. 1b?c). Patients
with solitary metastases (n = 41, 23 %) were excluded
from analyses of SD. No patients underwent metastasec-
tomy. To justify for the effect of tumor size on SD, we also
examined the potential use of alternative metric measures
of the metastases (SD divided by sum of diameters, SD
divided by mean diameter, SD divided by the square root
of the mean as well as SD divided by log mean) for their
potential use as markers for synchronized growth.
The median value of SD was used as cut-off value and
patients, were grouped as ‘‘low SD’’ and ‘‘high SD’’,
accordingly. Associations between different categorical
variables were assessed by Pearson’s Chi-square test.
Continuous variables not following the normal distribution
were compared between two or more groups using the
Mann–Whitney U tests. Univariate survival analyses were
performed by the product-limit procedure (Kaplan–Meier
method). Differences between categories were tested by the
log-rank test.
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Results
The key demographics and pathologic and clinical char-
acteristics of 180 patients recorded at the time of first
recurrence are shown in Table 1. A majority of the patients
were Stage 1–2 (88 %), ER ? (77 %), Her2- (77 %).
Bone- (38 %), lung- (30 %) and liver metastases (23 %)
were the most frequent metastatic sites. For the majority of
the patients (58 %), a CT-scan was the most appropriate
modality for tumor size measurements. For patients with
bone metastases, MRI (30 %) was the preferred modality,
whereas ultrasound (lymph nodes) and x-ray (bone
metastases and MRI contraindications) were used in some
cases (12 %).
Median time to recurrence was 53 months (2.6–305),
and no significant difference was present according to
stage, primary tumor grade, or Her2 status in this popula-
tion. ER negative patients (Log Rank p \ 0.001) and
younger patients (below median) (Log Rank p = 0.01) had
significantly shorter time to recurrence, median 28 versus
62 months and median 42 and 69, respectively. The annual
hazard rate of recurrence for the whole study population is
shown in Fig. 2.
Initially, we investigated the number and size of detec-
ted metastases in our patient population. The median
number of lesions measured was 7 (mean 6). Still, some
patients presented with more than 10 lesions and were
recorded as ‘‘[10’’, accordingly. Forty-one (23 %) patients
had only one measurable lesion at the time of first recur-
rence. Thus, SD was available in 142 patients. Median SD
in the population was 5.4 mm. Patients were grouped as
‘‘non-synchronized’’ if they had a SD above median or if
they had only one measurable lesion, and as ‘‘synchro-
nized’’ if they had a SD below median. Median sum of
diameters of metastatic lesions was 76 mm (10–697)
(Table 2).
We then analyzed in each patient the SD of metastatic
lesions in relation to time to recurrence. As illustrated in
Fig. 3a?b, the mean SD of metastatic lesions seemed to be
lower in the first 3 years after primary surgery, although
this trend was not statistically significant. Moreover, as
delayed recurrences as well as periods of tumor dormancy
are more evident in the node negative patient [23, 24], we
analyzed this group of patients separately. In this subset of
patients, there was a significantly lower SD in patients who
experienced early disease recurrence (B 3 years) when
compared to those with delayed recurrence [ 3 years
(median 3.1 vs. 5.7, Mann–Whitney test, p = 0.018)
(Fig. 3c?d). Similarly, SD was significantly lower during
the first three years after primary surgery in patients not
receiving systemic adjuvant treatment (median 2.5 vs. 6.4,
Mann–Whitney test, p = 0.005) (Fig 3e?f). There was no
significant association between SD and time after surgery
in patients receiving adjuvant systemic treatment.
Adjuvant endocrine treatment might affect the growth
kinetics of dormant micrometastases. Consequently, we
asked if a second drop in SD occurred at the time of
withdrawal of endocrine treatment (5 years of tamoxifen or
aromatase inhibitors). As expected, following the end of
endocrine treatment at year 5, there was a second drop in
SD (Fig 4a). When comparing the period just before end of
endocrine treatment (year 4–5) with the period immedi-
ately after end of endocrine treatment (year 5–8) SD was
significantly lower in the latter period (median 13.1 vs. 3.9,
Mann–Whitney test, p = 0.021, Fig 4b).
Low SD was significantly associated with low histo-
logical grade in primary tumors (Pearson Chi Square
p = 0.002), the absence of liver metastases (Pearson Chi
Fig. 1 Patient with multiple similar sized metastases at the time of
first recurrence and with low standard deviation (SD) of size and
number of metastatic lesions (a). Patient with one large liver
metastasis (red line) and two small metastases lung metastases at
the time of the first recurrence (only one is shown here, red arrow)
and with high SD (b, c)
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Square p = 0.001), and the presence of lung metastases
(Pearson Chi Square p = 0.02). No statistically significant
association was found between SD and ER status, Her2
status, radiology modality, nodal status, or stage. Other
metric measures of the metastases (see methods) did not give
significant information in addition to the analyses of SD.
Table 1 Patient characteristics
Number of patients Percent
Age
\40 6 3
40–49 25 14
50–59 43 24
60–69 48 27
C70 58 32
Nodal status
pN0 89 50
pN1 79 44
pN2 8 4
pN3 4 2
Tumor size
T1 (\2 cm) 74 41
T2 (2–5 cm) 92 51
T3 ([5 cm) 12 7
T4 2 1
Stage
1 47 26
2A 63 35
2B 49 27
3A 15 9
3B 2 1
3C 4 2
Grade
1 27 18
2 74 49
3 50 33
Missing 29
HR status
Neg 41 23
Pos 139 77
Her2 status
Neg 80 80
Pos 20 20
Missing 80
Adjuvant treatment
None 62 35
Endocrine 97 55
Chemotherapy 62 35
Radiology modalitya
CT-scan 104 58
MRI 55 30
Otherb 21 12
Metastatic site
Bone 68 38
Lymph nodes 31 17
Lung 54 30
Liver 41 23
Table 1 continued
Number of patients Percent
Brain 9 5
Other 21 12
Key demographic and pathological characteristics including age,
nodal status, tumor size, stage, grade, HR status, and Her2 status at
the time of primary surgery in 180 patients recorded with metastases
from breast cancer during 2005–2009 at Haukeland University Hos-
pital, Norway
a Refers to the radiology modality used for the analysis of metastases
number and size
b Ultrasound, chest x-ray, clinical measurement (caliper)
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Fig. 2 Annual recurrence hazard rate (± SE) in 180 patients
recorded with metastatic breast cancer at Haukeland university
Hospital during 2005–2009
Table 2 Metastatic pattern
Median Mean Min–max
Number of lesions counteda 7 6 1–[10
P
diameter of lesions per case (mm) 76 99 10–697
Standard deviation of lesions
per case (mm)
5.4 8.3 0–58
Time to recurrence (months) 53 69 2.6–305
Analysis of metastatic pattern at first recurrence in 180 cases of
metastatic breast cancer treated at Haukeland University Hospital,
Norway. Tumor measurements are in accordance with RECIST 1.1
a If [10 lesions, n = 10
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Finally, in the analyses of overall survival between time
of first recurrence and death, significantly increased sur-
vival was present in ER ? cases (Log Rank p = 0.05),
Her2 positive cases (Log Rank p = 0.008) as well as in
cases with low tumor load as measured by sum of diame-
ters of metastatic lesions at time of first recurrence (Log
Rank p = 0.001). No survival differences were present for
SD, liver metastases, lung metastases, stage at primary
diagnosis, or time between primary diagnosis and
recurrence.
Discussion
This study was initiated following the clinical observation
of variation in metastatic patterns in patients referred to our
ward at the time of first metastatic recurrence from breast
cancer. Whereas some patients presented with solitary or
oligometastases of varying size, other patients showed
multiple similar sized metastases in one or more organs.
We further observed that patients in the latter category
were frequently diagnosed with metastatic disease shortly
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Fig. 3 Metastatic pattern in 180 breast cancer patients. The plots
show the mean of the standard deviation (SD) of size and number of
metastases in each patient at first recurrence (± SE) according to time
after surgery. a All cases. b Box plot of mean SD according to early
recurrences (0–3 years) versus late recurrences (3 ? years), all cases.
c, d Node negative cases e, f Cases with no systemic adjuvant
treatment. *Mann–Whitney test
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after primary surgery, shortly after delayed breast recon-
struction, or shortly after end of adjuvant endocrine treat-
ment. Delayed recurrence of breast cancer metastases is
frequently observed in patients with estrogen receptor (ER)
positive disease in particular [5]. An annual recurrence rate
of 2 %, for as long as 15 years even after 5 years of
tamoxifen [25] or aromatase inhibitors [26], prevents these
patients from considering themselves as cured even for
decades.
The prominent variation in time between primary sur-
gery and first relapse in breast cancer suggests that there is
a great heterogeneity among patients or in the inherent
biology of the tumor cells per se. In some cases, a steady
growth of metastases and a constant risk of relapse can be
inferred by modeling the time of primary tumor detection
in relation to the time of relapse as well as the size and
number of metastases [27]. In addition, tumor dormancy
also in primary tumors is frequently found in the breast, the
prostate, and the thyroid gland of undiagnosed patients in
various autopsy materials [28], further supporting the
existence of growth inhibiting mechanisms or the absence
of growth stimulating signals.
In spite of otherwise favorable prognosis when com-
pared with node positive (N?) patients, some node nega-
tive (N0) patients do relapse with metastatic tumor growth.
In large patient series, the relapses observed in the node
negative patients also show a tendency of occurring later
when compared with node positive patients [23, 24]. Even
tiny tumors might eventually recur at distant sites in spite
of radical surgery at the primary stage. The station by
station model of breast cancer progression put forward by
Halsted over a century ago [29] followed by large and
mutilating ultra-radical surgery procedures has been
replaced by less invasive methods [30–33]. Recently, also
the value of lymph node dissection even in sentinel node
positive patients has been challenged [34]. The multimodal
approaches including limited surgery with immediate
reconstruction, limited irradiation, and effective systemic
adjuvant therapy, presently give the best total outcome
regarding both survival and quality of life. Nevertheless, in
spite of all the recent achievements in the treatment of
primary breast cancer, about 10 percent of patients even-
tually relapse [35]. Even if the concept of tumor dormancy
in breast cancer seems to be well established, several
controversies concerning the clinical impact exist [36].
Little is known about what mechanisms control dormancy
in human micrometastatic disease, and even more impor-
tant; what physiologic processes can cause the suspension
of dormancy and thereby fatal disease relapse. The Gom-
pertzian model of human breast cancer growth as discussed
by Norton [37], or more complicated models as suggested
by Speer et al. [38], can predict progression of the unper-
turbed primary tumor and are widely applied in the plan-
ning of adjuvant trials. Several mathematical models have
been applied to describe different relapse scenarios with
regard to time, size, and number of metastases [27, 37, 39].
Still, the lack of knowledge on the mechanisms controlling
tumor dormancy and tumor growth spurts renders these
models as crude approximations when it comes to pre-
dicting relapse in individual patients. The typically highly
variable remission periods between resection and relapse in
breast cancer patients are inexplicable by continuous
growth of metastases [40–42] and imply some degree of
growth restriction of occult micrometastases.
In theory, assuming a situation with a period of tumor
dormancy before, during or after primary surgery, the
likelihood of finding a solitary metastasis at the time of first
recurrence is statistically higher than finding multiple
metastases. This assumption is valid only if there is no
synchronized internal clock in the metastatic tumor cells or
no systemic signal to synchronize metastatic growth. Still,
in the clinic, we frequently observe patients with multiple
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Fig. 4 Metastatic pattern in the subgroup of breast cancer patients
treated with adjuvant endocrine therapy. a Mean of the standard
deviation (SD) of size and number of metastases in each patient at
first recurrence (± SE) according to time after surgery. b Box plot of
mean SD compared between the time before versus after cessation of
adjuvant endocrine treatment. *Mann–Whitney test
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similar sized metastases at first recurrence even many years
after removal of the primary tumor. These observations
support the concept that there might be a systemic event
simultaneously breaking the dormant state of micrometas-
tases. In addition to immunosuppression [11] and hormone
deprival [14], it has been suggested that wound healing
following the primary surgery might be one such syn-
chronizing signal, by turning on the angiogenic switch in
dormant micrometastases and thereby activating angio-
genesis [16–18]. The frequently observed peak in the
hazard ratio of relapse around 18 months, independent of
primary tumor stage [20, 25, 43], has been attributed to the
systemic response to primary surgery of breast tumors [44].
In order to find clinical support for a possible association
between time of primary surgery and synchronized growth
of dormant micrometastases, we studied the metastatic
pattern in 180 breast cancer patients at the time of first
recurrence. We established the SD of the measured sizes of
the metastases as a potential marker for synchronized
growth. It is a possible drawback in our material that our
patients, in most cases, presented with symptoms or bio-
chemical alterations before the diagnosis of recurrence was
established. In Norway, there is no requirement for routine
radiological examinations during follow-up. Thus, our data
does not give exact information on how long the lesions
might have been detectable by radiology ahead of diag-
nosis, nor of the growth rate. There is a possibility that the
power of SD as a marker for synchronized growth is
diluted by this weakness. Still, as a marker to identify cases
with low variation versus high variation in number and size
of metastases (i.e., synchronized vs. non-synchronized), SD
was superior to other metric estimates (see methods) by
computational simulation, especially when a Gompertzian
growth pattern was assumed. Nevertheless, there is a pos-
sibility that the size dependency of SD makes direct
comparison between the very small and the very large
metastatic lesions inaccurate. To our knowledge, this
approach has not been previously reported, and thus needs
to be confirmed in separate datasets.
We found that the SD was lower in early recurrences
(0–3 years after surgery), and this difference was statisti-
cally significant in node negative patients. The difference
between the node negative and the node positive patients
might be due to the difference in the overall prognosis. In
node positive patients, the micrometastatic spread is fre-
quently more advanced at the time of primary surgery and
the growth into macrometastases might already have been
initiated. In contrast, regarding the node negative patients,
our results indicate that the dormancy of systemic mi-
crometastases seems to be more susceptible to a systemic
synchronizing growth signal. This is in line with the
observed delayed recurrences in node negative patients in
large patient materials [23, 24]. Sixty-five percent of our
patients received systemic adjuvant treatment after primary
surgery. The sole intention of this treatment is to prevent or
at least delay growth of micrometastases, and this effect
was also reflected in a significantly lower SD in early
recurrences observed in cases not given adjuvant treatment.
This finding might suggest that adjuvant systemic treat-
ment prevents the effect of the synchronizing systemic
signal on the tumor cells during the time immediately after
surgery. Importantly, delayed initiation of adjuvant che-
motherapy has recently been shown to be associated with
significantly worse outcome [45], further underlining the
importance of the time window immediately following the
surgical procedure. We also cannot rule out the possibility
that the association between SD and time to recurrence
found in node negative cases is, in part, due to the
increased use of adjuvant treatment in node positive cases.
As expected, there was a second drop in SD directly after
end of adjuvant endocrine treatment in ER ? patients.
From this, we might infer that the removal of the estrogen
receptor or aromatase inhibitors acts as a second systemic
signal to synchronize growth of occult micrometastases
kept dormant during estrogen deprival. This expected
finding also serves as an internal control for the utility of
SD as a marker of synchronized growth. In comparison to
ER-, the ER? population recurs later [1], and this was
also the case in our study. An alternative explanation for
the delayed relapse and prolonged dormant state of the
slow growing ER? tumors could be the requirement of an
spontaneous enabling sub-clonal evolution in these cells
[46], which would occur independently in individual cells
over time. The subsequent macrometastases are then likely
to be asynchronous. Still, there was no significant associ-
ation between ER status and SD. This suggests that syn-
chronization occurs at a similar rate in ER positive and
negative patients. Low SD correlated with low histologic
grade in the primary tumors and suggests that synchronized
metastatic growth is more frequent in cases with lower
tumor heterogeneity. Still, no significant association
between histologic grade and time to recurrence was found.
Synchronized growth, quantified by low SD, showed an
inverse association in lung metastases and liver metastases.
Whereas in the lung, the SD was found to be lower when
compared with other sites, SD was significantly higher in
the liver, suggesting a different growth dynamic between
different organs. Still, most of our patients presented with
lesions at multiple sites. In a recent report by Cummings
et al. [47] 197 autopsies on patients that died of breast
cancer were examined in detail. Of a total of 150 patients,
the 46 patients who underwent surgical treatment of the
primary tumor were significantly more likely to develop
liver metastases, suggesting a role of acute wound healing
Breast Cancer Res Treat (2014) 146:627–636 633
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after surgery in activating dormant micrometastases in the
liver. Similar findings have also been reported by others
[48]. Experimental studies have also reported the role of
post-surgical wound healing in stimulating growth of liver
metastases [16]. Levels of wound healing associated
growth factors like Vascular Endothelial Growth Factor
show great heterogeneity between patients and also
between peripheral blood and locally at the wound site
[49]. Studies also show that levels of angiogenesis inhibi-
tors might change following surgery or radiation therapy of
the primary tumor [50, 51].
The effect of surgery on macrometastases has been an
unresolved issue addressed in multiple retrospective trials
studying the impact of removal of the breast in patients
with stage IV disease at presentation [52, 53]. Still, sev-
eral of these trials have been significantly biased based on
inclusion criteria. Nevertheless, surgical treatment in
patients with synchronous metastases is frequently rec-
ommended to increase local control, although overall
survival benefit remains to be proven [53]. Recently, a
clinical study on 350 women with stage IV disease at
presentation, randomized between surgical removal of
primary tumor and axillary lymph nodes and systemic
therapy, or systemic therapy alone, was presented by
Badwe et al. [54]. Although a significant increase in local
control was found, the distant site progression free sur-
vival was significantly decreased after surgery. Thus,
suggesting a detrimental effect of the surgical procedure,
as put forward by Fisher et al. [55]. No difference in
overall survival was found.
In conclusion, our results identify the standard deviation
of number and size of metastases at first recurrence as a
marker of synchronized growth of breast cancer metasta-
ses. Furthermore, significantly lower SD in early recur-
rences in node negative patients and patients not given
adjuvant systemic treatment suggests a link between the
surgical procedure and early synchronized metastatic
growth, which might be inhibited by systemic adjuvant
treatment. Further research that aim to identify the sys-
temic growth signals caused by surgery and wound healing,
might open additional therapeutic opportunities during the
time window around or immediately after surgical
intervention.
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